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1. Introduction 
Thyroid is a butterfly shaped gland composed of two encapsulated lobes, located on either 
side of the trachea just below the cricoid cartilage. This is connected by thin isthmus and is 
composed of spherical thyroid follicles, which contain the hormone in colloidal form. T3 and 
T4 are active hormones secreted under the control of TSH from adenohypophysis of 
pituitary gland. T3 is three to four fold more potent than T4. It is involved in normal growth 
and development in children temperature regulation, metabolism, energy production and 
intelligence in both children adults. It ensures normal growth and development of nervous 
system [1]. 
 
Fig. 1. Diagrammatic representation of variation of thyroid hormones in hypo and hyper 
thyroidism 
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The normal range of T4 is suggested to be 77-155nmol/L, T3 to 1.2 -2.8nmol/L ) and TSH 
to be 0.3-4 mU/L [2]. If the hormone levels are above or below the normal range, it leads 
to hyperthyroidism or hypothyroidism. The most common hypothyroid condition is 
Hashimoto’s thyroiditis in adults and congenital hypothyroidism in children. 
Hyperthyroid conditions include Graves’ disease, postpartum thyroiditis and 
thyrotoxicosis factitia. 
Hyperthyroidism also leads to a number of complications like heart problems, brittle bones 
(Osteoporosis), eye problems (Graves’ opthalmopathy) (Figure:2). 
    
Fig. 2. Symptoms of Graves’ disease 
Hypothyroidism describes an under active thyroid gland that is producing low level of 
thyroid hormone. Hypothyroid patients experience a variety of symptoms, including weight 
gain, intolerance to cold, goiter (enlarged thyroid), dry coarse, skin, fatigue, constipation, 
decreased heart rate, poor memory and depression.  
The most common form of hyperthyroidism is Graves’ disease (GD), an autoimmune 
disorder accounting for 60-80 % of all cases, in which the antibodies produced by immune 
system stimulates thyroid gland to produce excess of thyroxine. Normally, the immune 
system uses antibodies to protect against viruses, bacteria and other foreign substances that 
enter the body system. In GD, the antibodies mistakenly attack the thyroid gland and 
occasionally the tissues behind the eyes and the skin of lower legs over the shins. Though 
the exact cause of GD is not known, several factors including a genetic predisposition are 
likely to be involved (Figure:3). 
GD is an organ specific heterogeneous autoimmune disorder associated with T-lymphocyte 
abnormality affecting the thyroid eyes and skin. GD is also multifactorial disease that 
develops as a result of complex interaction between genetic susceptibility genes and 
environmental factors. Human leucocyte antigen (HLA) and cytotoxic T-lymphocyte 
associated molecule-4 (CTLA-4) are susceptibility candidates. CTLA_4 gene plays an 
important role in the development of GD, which is located on chromosome 2 q33. 
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Fig. 3. 
2. Cytogenetic location of CTLA-4 gene 
Cytogenetic Location: 2q33 
Molecular Location on chromosome 2: base pairs 204,732,510 to 204,738,682 
 
Fig. 4. The CTLA4 gene is located on the long (q) arm of chromosome 2 at position 33. 
More precisely, the CTLA4 gene is located from base pair 204,732,510 to base pair 
204,738,682 on chromosome 2. 
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Activation of T cells requires 2 signals transduced by the antigen specific TCR and co 
stimulatory ligand such as CD28. CTLA-4, which is expressed on activated T cells, bind to 
B7 present on antigen presenting cells and functions as a negative regulator of T cell 
activation. CTLA-4 gene polymorphism confers susceptibility to several autoimmune 
diseases, such as Graves’ disease (GD), Hashimoto’s thyroiditis (HT), Addison’s disease 
(AD), Insulin-dependent diabetes mellitus (IDDM), Rheumatoid arthritis (RA) and Multiple 
sclerosis. 
The activity of T cells requires a co stimulatory signal mediated by CD28/B7 interaction. 
The CTLA-4 gene product delivers a negative signal to T cells and mediates apoptosis. This 
CTLA-4 gene product is a T cell surface molecule that binds to the B 7 molecule on the 
antigen presenting cells (APCs). The CTLA-4 gene expression on T cells may affect the 
course of ongoing immune process. TSH receptor antibody (TRAb) causes Graves’ 
hyperthyroidism. 
The GD will go into remission during antithyroid drug (ATD) treatment. Remission of GD is 
predicted by a smooth decrease in TRAb during (ATD) treatment. Treatment of GD may 
involve surgery or use of radioactive iodine or use of ATD like propylthiouracil, 
methimazole and carbimazole. The genetic susceptibility to GD is also conferred by genes in 
human leucocyte antigen (HLA) and several other genes that are not linked to HLA. The 
present paper describes the association of GD with the CTLA-4 gene. 
The prevalence of hyperthyroidism has been reported to be 3.63% and hypothyroidism to be 
2.97% especially the females being more affected by hyperthyroidism [3]. Hence the current 
study deals with A/G single nucleotide polymorphism (SNP) at position 49 (exon1, codon 
17) of the CTLA-4 gene where in  Thr/Ala substitution and can be a function related marker. 
It has been shown to be associated with GD in Caucasians, Japanese, Koreans, Tunisians, 
Hong Kong Chinese children [2,4,5,6,7,8,9,10] and South Indains [11,12]. 
The polymorphism cited (A/G polymorphism in exon 1, C/T polymorphism in the 
promoter, and micro satellite repeat in 3’-untranslated region of exon 4) in CTLA-4 gene 
have been reported to be associated with autoimmune endocrine disorder. 
A/G polymorphism at position 49 in exon 1 of the CTLA-4 gene among South Indian 
population with Graves’ hyperthyroidism has revealed the frequencies of the GG genotype 
and “G” allele to the significantly higher in GD patients. The study has also demonstrated 
that GD patients had higher frequencies of “G” allele (GG genotype) and lower frequencies 
of “A” allele (AA genotype) than control group. 
Kinjo et al., (2000) have also reported the relationship between the CTLA-4 gene type and 
severity of the thyroid dysfunction. At diagnosis, free T4 concentrations were shown to be 
more in patients with the GG genotype and low in patients with the AA genotype. GD 
patients were reported to have more “G” allele than the control, suggesting that the CTLA-4 
GG genotype might induce down regulation of T-cell activation. If the function of CTLA-4 
with “G” alleles at position 49 in exon 1 is impaired CTLA-4 function may have d\difficulty 
in achieving remission. 
Identification of SNP 
We can analyze and identify all types of gene SNPs by Polymerase Chain Reaction (PCR) 
thermal cycler. 
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Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is a laboratory (in vitro) technique for generating large 
quantities of a specified DNA. Obviously, PCR is a cell-free amplification technique for 
synthesizing multiple identical copies (billions) of any DNA of interest, which was 
developed in 1994 by Karry Mullis (Nobel Prize, 1993). PCR is now considered as a basic 
tool for any molecular biologist. 
3. Primer designing [13] 
As oligonucleotide primers are useful for polymerase chain reaction (PCR), oligo 
hybridization and DNA sequencing, proper primer designing is actually one of the most 
important factors/steps. Various bioinformatics programs are available for selection of 
primer pairs from a template sequence. 
3.1 Guidelines for primer design 
When choosing two PCR amplification primers, the following guidelines should be 
considered: 
Primer length: It is accepted that optimal length of PCR primers is 18-22 bp (Wu et al., 1991) 
Melting temperature (Tm): It can be calculated using the formula of Wallace et al., 1997, Tm 
(oC) = 2(A+T)+4(G+C). The optimal melting temperature for primers ranges between 52-
58oC. Primers with melting temperature above 65oC should also be avoided because of 
potential for secondary annealing. 
Primer annealing temperature: The two primers of a primer pair should have closely 
matched melting temperatures for maximizing PCR product yield. The difference of 5oC or 
more each can lead to no amplification. 
( ) ( )a m mT  0.3 x T primer   0.7               T primer 14.9= + =  
Where, Tm (primer) = Melting Temperature of the primers, Tm (product) = Melting 
temperature of the product. 
GC Content: Primers should have GC content between 45 and 60 percent. GC content, 
melting temperature and annealing temperature are strictly dependent on one another  
.Dimers and false priming because misleading results: Presence of the secondary structures 
such as hairpins, self dimer produced by intermolecular or intramolecular interactions in 
primers can lead to poor or no yield of the product. 
Avoid Cross homology: To improve specificity of the primers it is necessary to avoid 
regions of homology 
3.2 Software for primer design  
NETPRIMER is software used to design and analyze the parameters of designed primer 
sequences using the following link http://premierbiosoft.com/netprimer/index.html 
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3.3 PCR standardization [13,14] 
PCR is a revolutionary technique used in almost all molecular biology experiments. In PCR, 
the repeated three-step process of denaturation, primer annealing and DNA polymerase 
extension results in exponential amplification of target DNA. Initially PCR was reported 
with E.Coli DNA polymerase Klenow fragment in 1985. In 1988, the first report on PCR 
using thermostable Taq DNA polymerase was published. Since then PCR has been 
extensively modified and used for various applications such as cloning, sequencing, site-
directed mutagenesis, diagnostics, genotyping, genome walking, amplification of RNA after 
reverse transcription for gene expression analysis amplification of a whole genome, etc. 
The central components of a PCR reaction are oligonucleotide primers, thermostable DNA 
polymerase, target DNA, dNTPs and reaction buffer including MgCl2. When a new PCR has 
to be developed, suitable primer pairs should be designed based on the target sequence,. 
Subsequently, the concentration of PCR components and the cycling conditions should be 
optimized. 
Thermostable enzymes: 
Thermostable enzymes should be selected based on the applications. High fidelity Taq DNA 
polymerase and proofreading recombinant enzymes are required for the amplification of 
more than 3 kb target sequence. For a standard PCR, 2 to 5 units of Taq DNA polymerase 
are recommended for a typical 100µl PCR. 
Deoxynucleoside triphosphate (dNTPs): 
For a standard PCR, 100 to 200 µM concentrations of dNTPs is used. The balanced solutions 
of all four nucleotides should be used to minimize the error frequency. The concentrations 
may be increased for Multiplex PCR and Repetitive PCR, where more than one PCR 
amplicons are expected. 
Template DNA: 
The purity and concentration of the template DNA are critical for a successful PCR 
amplification. For initial experiments, 0.1 to 200ng of the template DNA, based on the type 
can be used. For example, if it is a plasmid 0.1 to 1ng is sufficient. If the template is human 
genomic DNA, upto 200ng can be used. 
Primer concentrations: 
The primer concentration can affect the PCR. If the primer concentration is too low, 
amplifications will be failed; and if the concentration is too high, non-specific amplification 
will occur. Therfore, the primer concentration should be optimized empirically between 0.1 
to 1µM final concentrations. The most straightforward way of optimizing a PCR with a given 
primer pair is to change the concentration of MgCl2 or the annealing temperature or both. 
Optimization of primer annealing temperature: 
Optimization of the primer annealing temperature is the most critical step in PCR. The 
primer designing programs will suggest the Tm of the primers. In general, the annealing 
temperature should be set 2 to 5oC below the Tm of the primers. However, some 
oligonucleotides may not work optically at this temperature and hence the annealing 
temperature should be optimized using gradient PCR approach. 
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Optimization of MgCl2 concentration: 
Magnesium chloride is an essential component for PCR. It is a cofactor for Taq DNA 
polymerase. Mg++ promotes DNA/DNA interactions and forms complexes with dNTPs that 
are the actual substrates for Taq polymerase. When Mg++ is too low, primers fail to anneal 
to the target DNA. When Mg++ is too high, the base pairing becomes too strong and the 
amplicon fails to denature completely when you heat 94oC. MgCl2 concentration should be 
optimized for every PCR reaction. All the components of the reaction mixture can bind to 
magnesium ion, including primers, template, PCR products and dNTPs. Therefore, the 
concentration of MgCl2 has to be optimized for a new PCR. The most commonly used 
concentration of MgCl2 is 1.5mM and it can be optimized empirically between 1.5 and 4.0mM. 
 
Fig. 5. 
3.4 Genetic marker [15,16,17,18] 
A genetic marker is a gene or DNA sequence with a known location on a chromosome that 
can be used to identify cells, individuals or species. It can be described and observed as a 
variation which may arise due to mutation or alteration in the genomic loci. A genetic 
marker may be a short DNA sequence, such as a sequence surrounding a single base-pair 
change (single nucleotide polymorphism, SNP), or a long one, like minisatellites. For many 
years, gene mapping was limited in most organisms by traditional genetic markers which 
include genes that encode easily observable characteristics such as blood types or seed 
shapes.  
3.5 Some commonly used types of genetic markers 
RFLP (or Restriction fragment length polymorphism)  
SSLP (or Simple sequence length polymorphism)  
AFLP (or Amplified fragment length polymorphism)  
RAPD (or Random amplification of polymorphic DNA)  
VNTR (or Variable number tandem repeat)  
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Microsatellite polymorphism, SSR (or Simple sequence repeat)  
SNP (or Single nucleotide polymorphism)  
STR (or Short tandem repeat)  
SFP (or Single feature polymorphism)  
DArT (or Diversity Arrays Technology)  
RAD markers (or Restriction site associated DNA markers)  
They can be further categorized as dominant or co-dominant.  
Dominant markers allow for analyzing many loci at one time, e.g. RAPD. A primer 
amplifying a dominant marker could amplify at many loci in one sample of DNA with one 
PCR reaction. The dominant markers, as RAPDs and high-efficiency markers (like AFLPs 
and SMPLs), allow the analysis of many loci per experiment within requiring previous 
information about their sequence. 
Co-dominant markers analyze one locus at a time. A primer amplifying a co-dominant 
marker would yield one targeted product. so they are more informative because the allelic 
variations of that locus can be distinguished. As a consequence, we can identify linkage 
groups between different genetic maps but, for their development it is necessary to know 
the sequence (which is still expensive and is considered one of their down sides). Eg. RFLPs, 
microsatellites, etc.,  
3.6 Uses of genetic markers  
• Genetic markers can be used to study the relationship between an inherited disease and 
its genetic cause (for example, a particular mutation of a gene that results in a defective 
protein). It is known that pieces of DNA that lie near each other on a chromosome tend 
to be inherited together. This property enables the use of a marker, which can then be 
used to determine the precise inheritance pattern of the gene that has not yet been 
exactly localized. 
• Genetic markers have to be easily identifiable, associated with a specific locus and 
highly polymorphic, because homozygotes do not provide any information.  
• Detection of the marker can be direct by RNA sequencing, or indirect using allozymes. 
• Genetic Markers have also been used to measure the genomic response to selection in 
livestock.  
• Natural and artificial selection leads to a change in the genetic makeup of the cell. The 
presence of different alleles due to a distorted segregation at the genetic markers is 
indicative of the difference between selected and non-selected livestock.  
Hence, SNP (Single nucleotide polymorphism) in Graves’ hyperthyroidism is used as 
marker to identify which mutation is responsible for causing GD and other hereditary 
diseases. 
4. Analysis of CTLA-4 A/G polymorphism among South Indian population   
4.1 Protocol used for A/G single nucleotide polymorphism (SNP) study in Graves’ 
disease 
Genomic DNA was prepared from peripheral white cells using standardized protocol. We 
have analysed CTLA -4 genotypes and allele with PCR. PCR was performed with 
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oligonucleotide primers (Forward, 5’ – GCTCTACTTCCTGAAGACCT – 3’ and Revers, 5’ – 
AGTCTCACTCACCTTTGCAG – 5’)[2]. PCR was performed by initial denaturation 30 sec 
for 5 min. annealing for 45 sec at 57oC, extension for 30 sec at 72oC, denaturation 30 sec at 
94oC (for 20 cycles) and final extension for 7 min at 72oC. The PCR product was confirmed 
by agarose (1.8%) gel electrophoresis. The presence of G alleles was determined in each 
subject by PCR amplification of CTLA-4, followed by diffusion with Bbv1, which acts on the 
G variation, but not on the A variation. It a G allele was at position 49, 88/74 bp fragments 
were obtained. This was confirmed by 2% agarose gel. 
4.2 Restriction digestion 
The amplified CTLA-4 gene should be digested with the restriction enzyme Bbv1,which is 
commercially available. A typical 30µl reaction mix was used . Modify the required volume 
proportionately. 
PCR amplified product  – 20. 0µl 
10x buffer   - 3.0µl 
Bbv1(10units/ul)   - 1.0µl 
Deionized water   - 6.0µl 
Total    - 30.0µl 
Incubated the reaction mixture at 37OC for 4 hrs and inactivated by heating at 70oC for 10 
min. The product was confirmed using 2% agarose gel electrophoresis. 
4.3 Results 
The presence of genomic DNA confirmed by subjecting the agarose gel electrophoresis 
(0.7%) (Figure 6). The genomic DNA was then subjected to PCR and 162 bp fragments were 
obtained (Figure 7). The amplified PCR product digested with enzyme Bbv1, the restriction 
enzyme acts on the G variation, but not on the A variation. If a G allele was at position 49, 
88bp and 74bp fragments were obtained and the fragments were detected by 2% agarose gel 
electrophoresis (Figure 8). 
In the present study, the G/G genotype was observed in 32 (40 %) GD patients and in 26 
(32.50 %) individuals of the control group, A/G genotype was found in 37 (46.25 %) patients 
and in 25 (31.25 %) persons of the control group, A/A genotype was observed in 11 (13.75 
%) patients and in 29 (36.25 %) persons of the control group and G allele was found in 50 
(62.5%) GD patients and in 38 (47.5 %) persons of the control group, and A allele was found 
in 30 (37.5 %) GD patients and 42 persons (52.5%) of the  control group (Table 1). There was 
significant difference (p <0.05) in genotype and allelic frequency between the control group 
and GD patients. The present study also demonstrates an association between the CTLA-4 
gene polymorphism in Graves’ disease and with the remission rate of Graves’ 
hyperthyroidism. Among the GD cases studied, only 2% had remission. The frequencies of 
GG genotype (40 %) and G allele (62.5%) were higher when compared to A/A genotype 
(13.75%) and A allele (37.5 %) (Table 1).  
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Fig. 6. Confirmation of human genomic DNA 
 
Fig. 7. CTLA-4 gene amplification 
 
Fig. 8. Restriction analysis of CTLA-4 gene 
 
GENOTYPE 
 
GD patient (n=80) 
 
Control group 
(n=80)
G/G 32 (40%) 26 (32.50%) 
A/G 37 (46.25%) 25 (31.25%) 
A/A 11 (13.75%) 29 (36.25%) 
Allele   
G 50 (62.5%) 38 (47.5%) 
A 30 (37.5%) 42 (52.5%) 
Table 2. Prevalence of CTLA-4 gene genotype and allele frequency among South Indian 
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4.4 Discussion 
In the present study genomic DNA was isolated from patients and control groups and was 
subjected to Agarose gel electrophoresis (0.7%). This enables easy visualization of DNA 
band patterns. After confirming the presence of genomic DNA, it was subjected to PCR and 
162 bp fragments were obtained. The amplified PCR product was digested with enzyme 
Bbv1. The restriction enzyme acts on the G variation, but not on the A variation. If a G allele 
was at position 49, 88bp and 74bp two fragments were obtained. The PCR products were 
detected by 2% Agarose gel electrophoresis. 
A/G polymorphism at position 49 in exon 1 of the CTLA-4 gene among Madurai population 
with Graves’ hyperthyroidism revealed that the frequencies of the GG genotype and G allele 
were significantly higher in GD patients. This study has also revealed lower frequency (or 
absence) of A allele (AA genotype) than the control. CTLA-4 gene polymorphism has been 
reported to be associated with GD. CTLA-4 molecule is a member of the family of cell 
surface molecule CD28, which binds to B7. The CTLA-4/B7 complex competes with the 
CD28/B7 complex and delivers negative signals to the T-cells, which affects T-cell 
expansion, cytokine production, and immune responses as evidenced by Park et.al.[6] in 
Korean population, Yanagawa et al. [9] in Japanese population and  Yanagawa et al. [8] in 
Caucasian population. However, we do not know how CTLA-4 gene polymorphisms may 
contribute to the development of Graves’ hyperthyroidism. 
Three polymorphism sites (A/G polymorphism in exon 1; C/T polymorphism in the 
promoter, and micro satellite repeat in the 3’-untranslated region of exon 4) in the CTLA-4 
gene have been reported to be associated with autoimmune endocrine disorders. Kinjo et. 
al., [2] have reported the relationship between the CTLA-4 gene type and severity of the 
thyroid dysfunction. At diagnosis, free T4 concentrations were shown to be highest in 
patients with the GG genotype and lowest in patients with the AA genotype. GD patients 
have more G allele than control, suggesting that the CTLA-4 GG genotype might induce 
down regulation of T-cell activation. If the function of CTLA-4 with the G alleles at position 
49 in exon 1 was impaired CTLA-4 function might have difficulty in achieving remission.  
 
 Graves’ Disease
% (n = 144) 
Controls 
% (n = 110) 
Genotype   
G/G 50 (34.7) 26 (23.6) 
A/G 62 (43.1) 46 (41.8) 
A/A 32 (22.2) 38 (43.6) 
Table 3. Frequency of the genotype and allele of A/G polymorphism at position 49 in exon 1 
of CTLA-4 gene in GD patients and controls among Japanese –population. [2] 
Bednarczuk et. al., [4] analysed the association of CTLA-4 A49G polymorphism with Graves’ 
disease in Caucasian and Japanese population. Their study also reveals that, CTLA –4 G allele 
and G/G genotype confer genetic susceptibility to GD in Caucasian and Japanese population. 
The study of Kouki et. al., [5] among patients with GD revealed there were more individuals 
with G/G (17.8 %GD vs 11.6% of controls) or A/G CTLA-4 exon 1 genotypes (64.4 % GD vs 
53.5% control) and significantly fewer individuals with the A/A alleles (17.8 %GD vs 43.9 
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%control) when compared with controls. According to their findings, the frequency of the G 
allele was higher in GD patients (50%) than in controls (38.4%) in their population. 
There was significant difference between the control group and GD patients both in 
genotype and allelic frequency. Therefore, in accordance with previously published results, 
the present study also demonstrates an association between the CTLA-4 gene 
polymorphism in Graves’ disease and with the remission rate of Graves’ hyperthyroidism. 
Among the GD cases studied, only 2% had remission and the frequencies of GG genotype 
and G allele were higher when compared to A/A genotype and A allele. GD patient with G 
allele in exon 1 of the CTLA-4 gene were required to continue Anti thyroid drug (ATD) 
treatment [19] for longer periods to achieve remission. Further studies will be required to 
determine a clear association of the CTLA-4 gene polymorphism with the remission of GD. 
We have studied another gene polymorphism called PKD1 (C/T) at position 4058 in exon 45 
which is responsible for causing autosomal polycystic kidney disease (ADPKD) among 
South Indian. 
5. Short summary of C/T polymorphism in PKD1 gene 
Polycystic kidney disease (PKD) is a group of monogenic disorders that result in renal cyst 
development in kidney leads to kidney failure. Autosomal dominant polycystic kidney 
disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are two 
forms of PKD, which are largely limited to the kidney and liver, which extends from 
neonates to old age. ADPKD is a commonly inherited disorder in humans, with a frequency 
among the general population of 1 in 500. ADPKD caused by mutations in PKD1 gene (85%) 
located on human chromosome 16p13.3; the remaining 15% are caused by mutations in the 
PKD2 gene, located on human chromosome 4q21-23. A total of 60 ADPKD patients among 
South Indian (Madurai) population were analyzed. In genetic study, the genomic DNA was 
isolated, which would be subjects into PCR (Figure:9) and RFLP analysis (Figure:10). C/T 
polymorphism at position 4058 in exon 45 of the PKD1 gene among South Indian (Madurai) 
population with ADPKD revealed that the “TT” “CT’ genotype and the frequency of “T” 
allele was found be significantly (at p=0.001) higher in the patients compared to control 
subjects. The study was demonstrated that ADPKD patients had higher frequencies of “T” 
allele and lower frequency of “C” allele than control subjects. The present study also has 
been supported by Constantinides et al.,[20]. Therefore, the study reveals that there was an 
association of C/T polymorphism in ADPKD and the prevalence of ADPKD among South 
Indian (Madurai) population. 
 
Fig. 9. PKD1 gene amplification 
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Fig. 10. Restriction digestion PKD1 gene 
Hope this chapter will provide an insight on genetic screening of different disease and 
genetic disorders. 
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